Department of Breast Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China.
Institute of Immunology, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310058, China.
Int Immunopharmacol. 2021 Dec;101(Pt A):108191. doi: 10.1016/j.intimp.2021.108191. Epub 2021 Oct 1.
Neobavaisoflavone (Neo), is the active constituent of the herb Psoralea corylifolial, used in the traditional Chinese medicine, and has anti-inflammatory activity, but whether Neo could regulate colitis remains unclear. T helper 9 (T9) cells, a subset of CD4 T helper cells characterized by secretion of IL-9, have been reported to be involved in the pathogenesis of many autoimmune and inflammatory diseases, but whether Neo could control T9 cell differentiation also remains unclear. Here, we found that Neo could decrease IL-9 production of CD4 T cells by targeting PU.1 in vitro. Importantly, Neo had therapeutic effects on DSS-induced colitis. Furthermore, we identified T9 cells as the direct target of Neo for attenuating bowel inflammation. Therefore, Neo could serve as a lead for developing new therapeutics against inflammatory bowel disease.
新补骨脂异黄酮（Neo）是传统中药补骨脂的活性成分，具有抗炎活性，但 Neo 是否能调节结肠炎尚不清楚。辅助性 T 细胞 9（T9）细胞是 CD4 T 辅助细胞的一个亚群，其特征是分泌 IL-9，据报道，它参与了许多自身免疫和炎症性疾病的发病机制，但 Neo 是否能控制 T9 细胞分化仍不清楚。在这里，我们发现 Neo 可以通过靶向 PU.1 在体外减少 CD4 T 细胞中 IL-9 的产生。重要的是，Neo 对 DSS 诱导的结肠炎有治疗作用。此外，我们确定 T9 细胞是 Neo 减轻肠道炎症的直接靶点。因此，Neo 可以作为开发治疗炎症性肠病新疗法的先导化合物。
